Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II/III, Randomized, Double-blinded Study to Evaluate the Efficacy, Safety and Immunogenicity of a Booster Dose of PIKA Recombinant SARS-CoV-2 Vaccine in Adults Who Received 2 or More Doses of Inactivated Covid-19 Vaccine.

NCT05463419 is registered in ClinicalTrials.gov with Yisheng Biopharma (Singapore) Pte. Ltd. as lead sponsor.

NCT NCT05463419
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05463419 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II/III, Randomized, Double-blinded Study to Evaluate the Efficacy, Safety and Immunogenicity of a Booster Dose of PIKA Recombinant SARS-CoV-2 Vaccine in Adults Who Received 2 or More Doses of Inactivated Covid-19 Vaccine.
Lead sponsor
Yisheng Biopharma (Singapore) Pte. Ltd.
Phase
Phase 2/3
Overall status
Completed
Start date
October 3, 2022
Completion date
April 11, 2024
Enrollment
5,860 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 vaccine